Midatech Pharma Plc | CIK:0001643918 | 3

  • Filed: 4/24/2018
  • Entity registrant name: Midatech Pharma Plc (CIK: 0001643918)
  • Generator: Novaworks Software
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1643918/000121465918002960/0001214659-18-002960-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1643918/000121465918002960/mtph-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001643918
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory

    Internally generated intangible assets (development costs) 

    Expenditure on the research phase of an internal project is recognised as an expense in the period in which it is incurred. Development costs incurred on specific projects are capitalised when all the following conditions are satisfied:

      · Completion of the asset is technically feasible so that it will be available for use or sale

      · The Group intends to complete the asset and use or sell it

      · The Group has the ability to use or sell the asset and the asset will generate probable future economic benefits (over and above cost)

      · There are adequate technical, financial and other resources to complete the development and to use or sell the asset, and

      · The expenditure attributable to the asset during its development can be measured reliably.

    Judgement is applied when deciding whether the recognition criteria are met. Judgements are based on the information available. In addition, all internal activities related to the research and development of new projects are continuously monitored by the Directors.  The Directors consider that the criteria to capitalise development expenditure are not met for a product prior to that product receiving regulatory approval in at least one country.

    Development expenditure not satisfying the above criteria, and expenditure on the research phase of internal projects are included in research and development costs recognised in the Consolidated Statement of Comprehensive Income as incurred. No projects have yet reached the point of capitalisation.